Dr. Ekaterina (Kate) Dadachova joined USask in 2016. She is a Professor of Pharmacy at the College of Pharmacy and Nutrition. She held the Fedoruk Centre for Nuclear Innovation Chair in Radiopharmacy from 2016 to 2024. Before joining USask, she was a Professor of Radiology, Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA, where she was also Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research. She received her PhD in Physical Chemistry from Moscow State University in Moscow, Russia, and completed a postdoctoral fellowship in radiopharmaceutical chemistry at the Australian Nuclear Science and Technology Organization in Sydney, Australia.
Research
Dadachova’s laboratory has pioneered the treatment of infectious diseases including fungal and bacterial infections and HIV with radiolabeled antibodies (so called radioimmunotherapy). Her other research interests are radioimmunotherapy of melanoma, blood cancers and osteosarcoma as well as the development of melanin-based radioprotectors for cancer patients undergoing radiation therapy, soldiers on the battlefield and astronauts in space. She has an active research program which is funded by the Canadian Institutes of Health Research (CIHR), Saskatchewan Health Research Fund (SHRF), Canadian Space Agency (CSA), United States Department of Defense, National Institutes of Health (NIH), and the pharmaceutical industry. In 2020, she was recognized with a Distinguished Researcher Award from USask. Since January 2026, she serves as an Editor in Chief of Cancer Biotherapy and Radiopharmaceuticals. Dadachova is in the top 2% of cited scientists worldwide according to the Stanford University 2024 database.
See Dadachova’s publications in PubMed